Q1 2025 Management View CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase ...

Viking continued to build on the strong momentum achieved in 2024,” stated Brian Lian, Ph.D., chief executive officer of Viking. “Throughout the first quarter we continued to ramp up activities in ...

Stephanie Diaz; Manager of Investor Relations; Viking Therapeutics Inc. Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc. Greg Zante ...

Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the ...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian ...

Viking Therapeutics Inc (VKTX) reports significant progress in clinical trials and maintains a strong cash position despite ...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian ...

Welcome to the Viking Therapeutics First Quarter 2025 Financial ... Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution ...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian ...